Matches in SemOpenAlex for { <https://semopenalex.org/work/W3009123791> ?p ?o ?g. }
- W3009123791 abstract "Background: The standard sunitinib schedule to treat metastatic renal cell carcinoma (mRCC) is 4 weeks on/2 weeks off (4/2). However, some studies revealed intolerable adverse events (AEs) in patients on this schedule. An alternative schedule, 2 weeks on/1 week off (2/1), may overcome this issue. This meta-analysis was performed to compare the effectiveness and toxicity between the 2/1 and 4/2 sunitinib dosing schedules. Methods: We acquired relevant studies by searching PubMed, ScienceDirect, the Cochrane Library, Scopus, Ovid MEDLINE, Embase, Web of Science, and Google Scholar. Our main endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and AEs. Results: We identified 9 medium- and high-quality studies. Both schedules were effective for mRCC, with comparable OS and similar ORR. However, the 2/1 schedule had better PFS (hazard ratio (HR) = 0.81, 95% confidence interval [CI]: 0.66-0.99, P = 0.04), higher DCR [risk rate (RR) = 1.22, 95% CI: 1.01-1.47, P = 0.04] and fewer dosage interruptions (RR = 0.60, 95% CI: 0.43-0.84, P = 0.003). Additionally, the 2/1 schedule elicited fewer specific severe AEs, including thrombocytopenia/platelet disorder, hand-foot syndrome, hypertension, and fatigue. In our subanalysis, PFS was better among East Asians using the 2/1 schedule than among other populations (HR= 0.75, 95% CI: 0.58-0.98, P = 0.03), and patients administered an initial dosage of 50 mg/d on the 2/1 schedule had superior PFS (HR = 0.76, 95% CI: 0.59-0.97, P = 0.03) than those others. Conclusions: These findings suggest that the 2/1 schedule is more suitable for mRCC than 4/2, due to superior PFS, better DCR and fewer AEs. Nevertheless, more large-scale studies with good quality are needed." @default.
- W3009123791 created "2020-03-13" @default.
- W3009123791 creator A5000196124 @default.
- W3009123791 creator A5003628502 @default.
- W3009123791 creator A5012278873 @default.
- W3009123791 creator A5020727273 @default.
- W3009123791 creator A5035093874 @default.
- W3009123791 creator A5063835898 @default.
- W3009123791 creator A5064907989 @default.
- W3009123791 date "2020-03-06" @default.
- W3009123791 modified "2023-09-22" @default.
- W3009123791 title "A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis" @default.
- W3009123791 cites W1480729244 @default.
- W3009123791 cites W1562708731 @default.
- W3009123791 cites W1584237829 @default.
- W3009123791 cites W1946476244 @default.
- W3009123791 cites W1986215651 @default.
- W3009123791 cites W2019607817 @default.
- W3009123791 cites W2025444875 @default.
- W3009123791 cites W2038693293 @default.
- W3009123791 cites W2039698853 @default.
- W3009123791 cites W2061581498 @default.
- W3009123791 cites W2088095316 @default.
- W3009123791 cites W2089264350 @default.
- W3009123791 cites W2112075556 @default.
- W3009123791 cites W2113788015 @default.
- W3009123791 cites W2129407204 @default.
- W3009123791 cites W2135139265 @default.
- W3009123791 cites W2149456801 @default.
- W3009123791 cites W2160120519 @default.
- W3009123791 cites W2162427240 @default.
- W3009123791 cites W2165094466 @default.
- W3009123791 cites W2207224549 @default.
- W3009123791 cites W2414641360 @default.
- W3009123791 cites W2476027403 @default.
- W3009123791 cites W2567139842 @default.
- W3009123791 cites W2570719551 @default.
- W3009123791 cites W2585144179 @default.
- W3009123791 cites W2755626283 @default.
- W3009123791 cites W2790394626 @default.
- W3009123791 cites W2797198618 @default.
- W3009123791 cites W2886378688 @default.
- W3009123791 cites W2889642171 @default.
- W3009123791 cites W2911188335 @default.
- W3009123791 cites W2946704805 @default.
- W3009123791 cites W4236367536 @default.
- W3009123791 doi "https://doi.org/10.3389/fonc.2020.00313" @default.
- W3009123791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7069552" @default.
- W3009123791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32211333" @default.
- W3009123791 hasPublicationYear "2020" @default.
- W3009123791 type Work @default.
- W3009123791 sameAs 3009123791 @default.
- W3009123791 citedByCount "9" @default.
- W3009123791 countsByYear W30091237912020 @default.
- W3009123791 countsByYear W30091237912021 @default.
- W3009123791 countsByYear W30091237912022 @default.
- W3009123791 countsByYear W30091237912023 @default.
- W3009123791 crossrefType "journal-article" @default.
- W3009123791 hasAuthorship W3009123791A5000196124 @default.
- W3009123791 hasAuthorship W3009123791A5003628502 @default.
- W3009123791 hasAuthorship W3009123791A5012278873 @default.
- W3009123791 hasAuthorship W3009123791A5020727273 @default.
- W3009123791 hasAuthorship W3009123791A5035093874 @default.
- W3009123791 hasAuthorship W3009123791A5063835898 @default.
- W3009123791 hasAuthorship W3009123791A5064907989 @default.
- W3009123791 hasBestOaLocation W30091237911 @default.
- W3009123791 hasConcept C126322002 @default.
- W3009123791 hasConcept C143998085 @default.
- W3009123791 hasConcept C197934379 @default.
- W3009123791 hasConcept C207103383 @default.
- W3009123791 hasConcept C2776478404 @default.
- W3009123791 hasConcept C2777288759 @default.
- W3009123791 hasConcept C2777472916 @default.
- W3009123791 hasConcept C2779490328 @default.
- W3009123791 hasConcept C29730261 @default.
- W3009123791 hasConcept C44249647 @default.
- W3009123791 hasConcept C71924100 @default.
- W3009123791 hasConcept C95190672 @default.
- W3009123791 hasConceptScore W3009123791C126322002 @default.
- W3009123791 hasConceptScore W3009123791C143998085 @default.
- W3009123791 hasConceptScore W3009123791C197934379 @default.
- W3009123791 hasConceptScore W3009123791C207103383 @default.
- W3009123791 hasConceptScore W3009123791C2776478404 @default.
- W3009123791 hasConceptScore W3009123791C2777288759 @default.
- W3009123791 hasConceptScore W3009123791C2777472916 @default.
- W3009123791 hasConceptScore W3009123791C2779490328 @default.
- W3009123791 hasConceptScore W3009123791C29730261 @default.
- W3009123791 hasConceptScore W3009123791C44249647 @default.
- W3009123791 hasConceptScore W3009123791C71924100 @default.
- W3009123791 hasConceptScore W3009123791C95190672 @default.
- W3009123791 hasFunder F4320321001 @default.
- W3009123791 hasFunder F4320322665 @default.
- W3009123791 hasLocation W30091237911 @default.
- W3009123791 hasLocation W30091237912 @default.
- W3009123791 hasLocation W30091237913 @default.
- W3009123791 hasLocation W30091237914 @default.
- W3009123791 hasLocation W30091237915 @default.
- W3009123791 hasLocation W30091237916 @default.
- W3009123791 hasOpenAccess W3009123791 @default.
- W3009123791 hasPrimaryLocation W30091237911 @default.